Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
Status:
Suspended
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and
obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma.